{"id":451,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"cagrilintide-amylin-analog-phase-2-evidence","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/cagrilintide-amylin-analog-phase-2-evidence\/","title":{"rendered":"Cagrilintide en tant qu'analogue de l'amyline \u00e0 action prolong\u00e9e\u00a0: lecture des preuves de la phase 2"},"content":{"rendered":"
Cagrilintide est un analogue de l'amyline \u00e0 action prolong\u00e9e d\u00e9velopp\u00e9 pour une \u00e9tude une fois par semaine. Il appartient \u00e0 une cat\u00e9gorie de signalisation diff\u00e9rente des agonistes des r\u00e9cepteurs GLP-1, m\u00eame si des programmes cliniques ult\u00e9rieurs ont \u00e9valu\u00e9 le cagrilintide avec le s\u00e9maglutide.<\/p>
Points cl\u00e9s \u00e0 retenir<\/h2>
Cagrilintide est un analogue de l'amyline\u00a0; le s\u00e9maglutide est un agoniste des r\u00e9cepteurs GLP-1.<\/li>
Les preuves 2 en monoth\u00e9rapie en phase doivent \u00eatre distingu\u00e9es des essais ult\u00e9rieurs d'association CagriSema.<\/li>
D'apr\u00e8s les informations examin\u00e9es sur le FDA, le cagrilintide n'est pas un composant d'un m\u00e9dicament approuv\u00e9 par le FDA.<\/li><\/ul><\/div><\/div>Illustration originale en laboratoire de la recherche sur les r\u00e9cepteurs peptidiques\u00a0; les parcours sont conceptuels et ne contiennent aucune donn\u00e9e d\u2019essai.<\/figcaption><\/figure>
Pourquoi l'amyline est une voie de recherche distincte<\/h2>
L'amyline est co-s\u00e9cr\u00e9t\u00e9e avec l'insuline et participe \u00e0 la signalisation li\u00e9e aux nutriments. Cagrilintide a \u00e9t\u00e9 con\u00e7u pour une exposition prolong\u00e9e par rapport \u00e0 l\u2019amyline native. La pharmacologie de ses r\u00e9cepteurs et sa conception mol\u00e9culaire ne sont pas interchangeables avec l'agonisme des r\u00e9cepteurs GLP-1, GIP ou le glucagon.<\/p>
Qu\u2019apporte l\u2019essai de phase 2<\/h2>
L'essai randomis\u00e9 de phase 2 a compar\u00e9 plusieurs groupes de doses de cagrilintide avec un placebo et un comparateur actif chez des adultes en surpoids ou ob\u00e8ses. Il a \u00e9valu\u00e9 l'\u00e9volution du poids corporel et de la s\u00e9curit\u00e9 au cours de la p\u00e9riode d'\u00e9tude. Le document soutenait la poursuite du d\u00e9veloppement mais ne faisait pas du cagrilintide un m\u00e9dicament approuv\u00e9.<\/p>
Lors du r\u00e9sum\u00e9 de l'essai, les d\u00e9tails utiles sont la population, la randomisation, le comparateur, la dur\u00e9e, le crit\u00e8re d'\u00e9valuation principal et le profil des \u00e9v\u00e9nements ind\u00e9sirables. Copier un pourcentage maximum sans ces qualificatifs ne constitue pas un examen ad\u00e9quat des preuves.<\/p>
Classe de mol\u00e9cule<\/strong>Analogue d'amyline \u00e0 action prolong\u00e9e<\/span><\/div>
Type de preuve<\/strong>Essai randomis\u00e9 en phase humaine 2<\/span><\/div>
Limite de d\u00e9veloppement<\/strong>Enqu\u00eate; non \u00e9quivalent aux produits \u00e0 base de s\u00e9maglutide approuv\u00e9s<\/span><\/div><\/div><\/div>
L'agent unique n'est pas la m\u00eame chose que CagriSema<\/h2>
CagriSema fait r\u00e9f\u00e9rence \u00e0 l'administration concomitante de cagrilintide et de s\u00e9maglutide dans le cadre de programmes cliniques sp\u00e9cifi\u00e9s. Les r\u00e9sultats de cette combinaison ne peuvent pas \u00eatre pr\u00e9sent\u00e9s uniquement sous forme de r\u00e9sultats pour le cagrilintide, et aucun des deux ensembles de donn\u00e9es ne valide un m\u00e9lange fourni de mani\u00e8re ind\u00e9pendante \u00e0 moins que l'\u00e9quivalence et la qualit\u00e9 du produit ne soient \u00e9tablies.<\/p>","protected":false},"excerpt":{"rendered":"
Un guide fond\u00e9 sur des sources sur la pharmacologie des r\u00e9cepteurs de l'amyline du cagrilintide, la conception de l'essai de phase 2 et la fronti\u00e8re entre les preuves \u00e0 agent unique et celles combin\u00e9es.<\/p>","protected":false},"author":1,"featured_media":621,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"320","pim_article_type":"Clinical evidence review","pim_evidence_level":"Randomized phase 2 human trial; investigational single-agent context","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Once-weekly cagrilintide in people with overweight and obesity \u2014 phase 2 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34798060\/\",\"note\":\"Primary randomized phase 2 record; PMID 34798060.\"},{\"title\":\"FDA information on cagrilintide and other unapproved GLP-1-related products\",\"url\":\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss\",\"note\":\"Current regulatory-status boundary.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-451","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\n
Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence - NHD<\/title>\n<meta name=\"description\" content=\"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/cagrilintide-amylin-analog-phase-2-evidence\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence\" \/>\n<meta property=\"og:description\" content=\"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/cagrilintide-amylin-analog-phase-2-evidence\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\"},\"wordCount\":284,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\",\"name\":\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-amylin-analog-phase-2-evidence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cagrilintide en tant qu'analogue de l'amyline \u00e0 action prolong\u00e9e\u00a0: lecture des preuves de la phase 2 - NHD","description":"Un guide fond\u00e9 sur des sources sur la pharmacologie des r\u00e9cepteurs de l'amyline du cagrilintide, la conception de l'essai de phase 2 et la fronti\u00e8re entre les preuves \u00e0 agent unique et celles combin\u00e9es.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/cagrilintide-amylin-analog-phase-2-evidence\/","og_locale":"fr_FR","og_type":"article","og_title":"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence","og_description":"A source-grounded guide to cagrilintide\u2019s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.","og_url":"https:\/\/nhdbio.com\/fr\/cagrilintide-amylin-analog-phase-2-evidence\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"},"wordCount":284,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/","url":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/","name":"Cagrilintide en tant qu'analogue de l'amyline \u00e0 action prolong\u00e9e\u00a0: lecture des preuves de la phase 2 - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Un guide fond\u00e9 sur des sources sur la pharmacologie des r\u00e9cepteurs de l'amyline du cagrilintide, la conception de l'essai de phase 2 et la fronti\u00e8re entre les preuves \u00e0 agent unique et celles combin\u00e9es.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-amylin-analog-phase-2-evidence-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/cagrilintide-amylin-analog-phase-2-evidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=451"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/451\/revisions"}],"predecessor-version":[{"id":520,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/451\/revisions\/520"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/621"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Chercheur](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png\")